A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : GVHD / graft-versus-host disease

[Related PubMed/MEDLINE]
Total Number of Papers: 10953
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   GVHD  (>> Co-occurring Abbreviation)
Long Form:   graft-versus-host disease
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 18F-FDG PET/CT in Graft Versus Host Disease-Associated Polymyositis. ---
2020 A case of hepatosplenic T-cell lymphoma successfully treated by HLA haploidentical stem cell transplantation. CR, HSTL, PCR
2020 A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature. CNS, DMTs, HSCT, MOG, MS, NMO
2020 A clinical and histological comparison between acute cutaneous graft-versus-host disease and other maculopapular eruptions following hematopoietic stem cell transplantation: a retrospective cohort. MP, OR
2020 A comparison of post-transplantation cyclophosphamide versus antithymocyte-globulin in patients with hematological malignancies undergoing HLA-matched unrelated donor transplantation. ATG, HLA, HSCT, PTCy
2020 A high CD34+ cell dose is associated with better disease-free survival in patients with low-risk diseases undergoing peripheral blood stem cell transplantation from HLA-matched related donors. DFS, HLA, HR, PBSCT
2020 A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis. MF, SCT, TRM, TRM
2020 A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. allo-HCT, DLT, HMs, irAEs, PD-1
2020 A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703. BMT CTN, HCT, PTCy
10  2020 A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study. AML, DFS, HSCT, KIR, NK, OS, URD
11  2020 A prospective evaluation on the interaction of fluconazole and voriconazole on serum concentrations of budesonide in patients treated for gastrointestinal GVHD. allo-HSCT, GI
12  2020 A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis. PTCy, SPGF
13  2020 A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort. GSS, IST, NRM, OS
14  2020 A real life use of ruxolitinib in patients with acute and chronic graft versus host disease refractory to corticosteroid treatment in Latin American patients. ---
15  2020 A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe. allo-HCT
16  2020 A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. HCT, IFIs, IQR
17  2020 A single-nucleotide polymorphism in the human ENTPD1 gene encoding CD39 is associated with worsened graft-versus-host disease in a humanized mouse model. donorsAA, SNP
18  2020 A study of human leukocyte antigen-haploidentical hematopoietic stem cells transplantation combined with allogenic mesenchymal stem cell infusion for treatment of severe aplastic anemia in pediatric and adolescent patients. haplo-HSCT, HLA, MSCs, SAA
19  2020 Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease. RIC, SCD, SCT, URD
20  2020 Aberrant HLA-DR expression in the conjunctival epithelium after autologous serum treatment in patients with graft-versus-host disease or Sjogren's syndrome. AS, DED, HLA, SS
21  2020 ABO-Incompatible Kidney Transplantation After Bone Marrow Transplantation: A Case Report. HSCT
22  2020 Acute Graft-Versus-Host Disease: A Brief Review aGvHD, allo-HSCT
23  2020 Acute Graft-versus-Host Disease: Emerging Insights and Updates into Detection, Prevention, and Treatment. HCT
24  2020 Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. CES-D, HR, OR
25  2020 Adipose tissue-derived stromal cells retain immunosuppressive and angiogenic activity after coculture with cord blood hematopoietic precursors. ASCs, CB, HSPCs, IDO, LIF, MNCs
26  2020 Advanced glycation end products and chronic inflammation in adult survivors of childhood leukemia treated with hematopoietic stem cell transplantation. AGEs, ALL, CV, HSCT, TBI
27  2020 Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation. allo-HSCT, NAC, PGF, ROS, SCB
28  2020 Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. allo-BMT, ART
29  2020 Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. allo-BMT, CI, CLL, NMA, PTCy
30  2020 Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group. MM, OS, PFS
31  2020 Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. AA, CY
32  2020 Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: Multicenter Analysis by the Polish Adult Leukemia Group. allo-HSCT, BMF/PNH, cPNH, OS, PNH
33  2020 Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study. 2-haplo-mismatch HSCT, HSCT
34  2020 Allogeneic Peripheral Blood Stem Cell Transplant: Correlation of Donor Factors with Yield, Engraftment, Chimerism, and Outcome: Retrospective Review of a Single Institute During a 3-Year Period. CD, MUD, PBSC
35  2020 Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin. AML, ATG, BM, cGVHD, CI, GRFS, GRSF, HLA, HR, PBSC
36  2020 Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma-Romanian Experience. ATLL, HTLV-I, MRD
37  2020 Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. allo-HCT, CLL, NAs, OS, PFS
38  2020 Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. GRFS, LFS, OS, RI, RR-ALL, TBI
39  2020 Alteration in the Skin Microbiome in Cutaneous Graft Versus Host Disease. ---
40  2020 Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease. EBV
41  2020 Alternative donor: alphass/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease. HSCT, MSD, MSD, SCD
42  2020 Alternative mechanisms that mediate graft-versus-host disease in allogeneic hematopoietic cell transplants. aGVHD, allo-HCT, APCs, MiHA
43  2020 An Animal Model That Mimics Human Herpesvirus 6B Pathogenesis. HHV-6B
44  2020 An intestinal organoid-based platform that recreates susceptibility to T-cell-mediated tissue injury. ---
45  2020 Anaerobic Antibiotics and the Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. CI, HR, HSCT
46  2020 Analysis of Busulfan in Plasma by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). ---
47  2020 Analysis of Cell Subsets in Donor Lymphocyte Infusions from HLA Identical Sibling Donors after Allogeneic Hematopoietic Cell Transplant. allo-HCT, DLIs, TN
48  2020 Analysis of determinant factors of liver fibrosis progression in ex-thalassemic patients. allo-HSCT, BMSC, TE
49  2020 Analysis of Risk Factors Associated With Poor Outcome in Posterior Reversible Encephalopathy Syndrome After Treatment in Children: Systematic Review and Meta-Analysis. CIs, CNS, HSCT, ORs, PRES, SCD
50  2020 Anti-Apoptotic Molecule BCL2 Is a Therapeutic Target in Steroid-Refractory Graft-Versus-Host Disease. Bcl-2
51  2020 Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. ASCT, ATG, PBSC
52  2020 Application of latent class analysis in diagnosis of graft-versus-host disease by serum markers after allogeneic haematopoietic stem cell transplantation. AUC, Cr, GS, HSCT, LDH, UA
53  2020 ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome. GVL
54  2020 Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant recipients: study protocol for the prospective multicentre OptimBioma study. HSCT
55  2020 Assessment of ST2 and Reg3a Levels in Patients with Acute Graft-versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. REG3A, ST2
56  2020 Association between Vitamin D and Risk for Early and Late Post-Transplant Complications. HSCT, VD, VDL, VOD
57  2020 Association of Alemtuzumab Induction With a Significantly Lower Incidence of GVHD Following Intestinal Transplantation: Results of 445 Consecutive Cases From a Single Center. LI, MV
58  2020 Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. AKI, allo-HSCT, SNPs
59  2020 Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. Flu-Bu, Flu-Cy, Flu-Cy-2GyTBI, HCT, HR, RIC-NMAC
60  2020 Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working Party. allo-SCT, CI, HR
61  2020 Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy. irAEs
62  2020 ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. GRFS, HSCT, MMUD, MUD, NRM, UCB
63  2020 Autoimmune cytopenias following allogeneic hematopoietic stem cell transplant in pediatric patients: Response to therapy and late effects. AICs, allo-HSCT
64  2020 Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation. AHSCT
65  2020 BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions. CI, DLI, HR, MDRC, MDRCm, MDRCt, MMUD, MSD, MUD, NRM
66  2020 Bendamustine Conditioning Skews Murine Host DCs Toward Pre-cDC1s and Reduces GvHD Independently of Batf3. BMT, DCs, WT
67  2020 Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia. BEN-TBI, BMT, CY, GVL, HCT
68  2020 Berberine combined with cyclosporine A alleviates acute graft-versus-host disease in murine models. allo-HSCT, AST, BBR, CsA, NF-kappaB, Th1
69  2020 Better Failure-Free Survival and Graft-versus-Host Disease-Free/Failure Free Survival with Fludarabine-Based Conditioning in Stem Cell Transplantation for Aplastic Anemia in Children. AA, CY, FFS, Flu, IST, OS, SCT
70  2020 Biomarkers for Allogeneic HCT Outcomes. GVT, HCT
71  2020 Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. AVN, BMD, FAQs, HCT
72  2020 Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes? BM, PTCy, TNC
73  2020 Bone Marrow Transplantation in Congenital Erythropoietic Porphyria: Sustained Efficacy but Unexpected Liver Dysfunction. CEP, HSCT, UROS
74  2020 Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease. BMT, DCs, GVL
75  2020 Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. ALL, BM, GRFS, haplo-HCT, HR, LFS, NRM, OS, PB, PTCy
76  2020 Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance. APCs, FasL, GVL, HSCT, MPBC
77  2020 Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation. aGVHD, allo-SCT, cGVHD, CMV, CNIs, EBV, HRD, NK/T
78  2020 Can we prevent or treat graft-versus-host disease with cellular-therapy? iNKTs, MDSCs, MSCs
79  2020 Capsule Endoscopy after Hematopoietic Stem Cell Transplantation Can Predict Transplant-Related Mortality. allo-SCT, CE, CMV, TRM
80  2020 CAR-NK for tumor immunotherapy: Clinical transformation and future prospects. CAR-T, NK
81  2020 Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial. ---
82  2020 Case 281. ---
83  2020 Case 281: Thoracic Air Leak Syndrome in a Patient with Hematopoietic Stem Cell Transplantation and Graft-versus-Host Disease. ---
84  2020 CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. GI, HSCT
85  2020 CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). AML, EBMT, HR, HSCT, LFS, NRM, OS
86  2020 CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells. CMV, EBV
87  2020 CD52-negative T cells predict acute graft-versus-host disease after an alemtuzumab-based conditioning regimen. CCR5, GARP, GITR, HSCT, ILT3, RIC
88  2020 CD8+ T cells mediate ultraviolet A-induced immunomodulation in a model of extracorporeal photochemotherapy. CHS, ECP, i.v
89  2020 Cell-based immunomodulatory therapy approaches for type 1 diabetes mellitus. BM, MSCs, T1DM
90  2020 Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance. ---
91  2020 Challenges and Pitfalls in the Engineering of Human Interleukin 22 (hIL-22) Secreting Lactobacillus reuteri. hIL-22, IBD, IL-10, Reg3alpha
92  2020 Challenging and Practical Aspects of Nutrition in Chronic Graft-versus-Host Disease. ---
93  2020 Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival. allo-HSCT, RIC
94  2020 Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. CPIs, HR, NRM, OS, PD, PFS, PTCy, SCT, SD
95  2020 Chinese Medicine Treatment on Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. CM
96  2020 Chronic graft-versus-host disease and inhibition of interleukin-17: proof of concept in humans. ---
97  2020 Chronic Graft-Versus-Host Disease in Pancreas After Kidney Transplant Recipients - An Unrecognized Entity. cGVHD
98  2020 Clinical Factors Affecting the Dose Conversion Ratio from Intravenous to Oral Tacrolimus Formulation among Pediatric Hematopoietic Stem Cell Transplantation Recipients. HCT
99  2020 Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation. ATG, CI, ECGVHD, HLA, HR, HSCT, TBI
100  2020 Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation. HR, HSCT, JMML, OS